Form 4: Travere Therapeutics CCO Sells Shares

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the sale of 5,591 shares and a charitable gift of 1,078 shares of common stock.

Summary

• Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc. (TVTX), reported changes in his beneficial ownership of common stock.
• He sold 5,591 shares of common stock at a price of $35 per share on October 31, 2025.
• He also made a charitable gift of 1,078 shares of common stock on November 3, 2025, with a transaction price of $0.
• Both transactions were executed under a Rule 10b5-1(c) plan adopted on June 16, 2025.
• Following these transactions, Peter Heerma beneficially owns 117,993 shares of Travere Therapeutics common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in insider ownership. However, the pre-planned nature of the transactions under a Rule 10b5-1 plan mitigates the negative signal, suggesting the sale was not based on new, undisclosed adverse information.

Negatives

• Reduction in insider ownership by the Chief Commercial Officer, which could be perceived as a slight negative signal by some investors.

Future Outlook

Not applicable, as this filing reports past insider transactions and does not provide forward-looking statements or guidance.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May perceive the reduction in insider ownership as a slight negative, though the 10b5-1 plan provides context that the sale was pre-scheduled.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, these transactions were conducted under a pre-arranged 10b5-1 plan, indicating they were not based on new, material non-public information. A single Form 4 filing, especially one involving a 10b5-1 plan, typically does not warrant a change in investment recommendation without additional fundamental analysis or other significant news.

Keywords

Travere Therapeutics, TVTX, Peter Heerma, Chief Commercial Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Disposition